Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alan David D'Andrea, M.D.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Mentoring
In Vitro Androgen Therapy of Bone Marrow from Patients with Fanconi Anemia
Full Time/Year Long, 05/04/02 - 04/26/02
Analysis of the FAA/FAC Complex
Summer, 06/04/99 - 07/30/99
Proteasome Inhibition as a Promising Target for Subtype-Specific Glioblastoma Therapy
Summer, 02/02/09 - 12/31/09
In Vitro Androgen Therapy of Bone Marrow from Patients with Fanconi Anemia PASTEUR
Full Time/Year Long, 05/04/01 - 04/26/02
Molecular and Cellular Biology of Fanconi Anemia: Investigating the Possible Role of Ik Beta -Kinase Beta in FANCA Protein Phosphonylation
Summer, 06/01/99 - 07/15/99

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA240243 (D'ANDREA, ALAN D.) Aug 3, 2020 - Jul 31, 2025
    NIH/NCI
    Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
    Role: Principal Investigator
  2. P50CA168504 (WINER, ERIC P) Sep 17, 2013 - May 31, 2024
    NIH/NCI
    Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
    Role: Co-Principal Investigator
  3. RC4DK090913 (D'ANDREA, ALAN DAVID) Sep 23, 2010 - Aug 31, 2013
    NIH/NIDDK
    Novel therapies for Fanconi anemia
    Role: Principal Investigator
  4. U19AI067751 (D'ANDREA, ALAN DAVID) Aug 31, 2005 - Jul 31, 2011
    NIH/NIAID
    Centers for Medical Countermeasures Against Radiation
    Role: Principal Investigator
  5. R13DK054005 (D'ANDREA, ALAN DAVID) Apr 24, 1998 - Dec 31, 1998
    NIH/NIDDK
    CONFERENCE ON SIGNAL TRANSDUCTION BY JAKS AND STATS
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 Oct 29; JCO2002151. PMID: 33119476.
    Citations:    
  2. Li F, Kozono D, Deraska P, Branigan T, Dunn C, Zheng XF, Parmar K, Nguyen H, DeCaprio J, Shapiro GI, Chowdhury D, D'Andrea AD. CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. Mol Cell. 2020 Nov 05; 80(3):410-422.e6. PMID: 33108758.
    Citations:    
  3. Sarangi P, Clairmont CS, Galli LD, Moreau LA, D'Andrea AD. p31comet promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase. Proc Natl Acad Sci U S A. 2020 Oct 27; 117(43):26795-26803. PMID: 33051298.
    Citations:    Fields:    
  4. Rodríguez A, Zhang K, Färkkilä A, Filiatrault J, Yang C, Velázquez M, Furutani E, Goldman DC, García de Teresa B, Garza-Mayén G, McQueen K, Sambel LA, Molina B, Torres L, González M, Vadillo E, Pelayo R, Fleming WH, Grompe M, Shimamura A, Hautaniemi S, Greenberger J, Frías S, Parmar K, D'Andrea AD. MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. Cell Stem Cell. 2020 Sep 24. PMID: 32997960.
    Citations:    Fields:    
  5. Patterson-Fortin J, D'Andrea AD. Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy. Cancer Res. 2020 Nov 01; 80(21):4593-4600. PMID: 32651257.
    Citations: 1     Fields:    
  6. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968. PMID: 32553118.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  7. Carbone M, Arron ST, Beutler B, Bononi A, Cavenee W, Cleaver JE, Croce CM, D'Andrea A, Foulkes WD, Gaudino G, Groden JL, Henske EP, Hickson ID, Hwang PM, Kolodner RD, Mak TW, Malkin D, Monnat RJ, Novelli F, Pass HI, Petrini JH, Schmidt LS, Yang H. Tumour predisposition and cancer syndromes as models to study gene-environment interactions. Nat Rev Cancer. 2020 Sep; 20(9):533-549. PMID: 32472073.
    Citations:    Fields:    
  8. Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell. 2020 06 18; 78(6):1070-1085. PMID: 32459988.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  9. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543. PMID: 32424117.
    Citations:    Fields:    
  10. Sarangi P, Clairmont CS, D'Andrea AD. Disassembly of the Shieldin Complex by TRIP13. Cell Cycle. 2020 Jul; 19(13):1565-1575. PMID: 32420796.
    Citations:    Fields:    
  11. Li N, Wang J, Wallace SS, Chen J, Zhou J, D'Andrea AD. Cooperation of the NEIL3 and Fanconi anemia/BRCA pathways in interstrand crosslink repair. Nucleic Acids Res. 2020 04 06; 48(6):3014-3028. PMID: 31980815.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  12. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459. PMID: 32193378.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  13. Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020 05; 31(5):590-598. PMID: 32245699.
    Citations: 5     Fields:    
  14. Cai MY, Dunn CE, Chen W, Kochupurakkal BS, Nguyen H, Moreau LA, Shapiro GI, Parmar K, Kozono D, D'Andrea AD. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection. Cell Rep. 2020 02 18; 30(7):2402-2415.e5. PMID: 32075772.
    Citations: 1     Fields:    
  15. Clairmont CS, Sarangi P, Ponnienselvan K, Galli LD, Csete I, Moreau L, Adelmant G, Chowdhury D, Marto JA, D'Andrea AD. TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat Cell Biol. 2020 01; 22(1):87-96. PMID: 31915374.
    Citations: 5     Fields:    Translation:HumansCells
  16. Pouliot GP, Degar J, Hinze L, Kochupurakkal B, Vo CD, Burns MA, Moreau L, Ganesa C, Roderick J, Peirs S, Menten B, Loh ML, Hunger SP, Silverman LB, Harris MH, Stevenson KE, Weinstock DM, Weng AP, Van Vlierberghe P, D'Andrea AD, Gutierrez A. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS One. 2019; 14(11):e0221288. PMID: 31721781.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  17. Rajkumar-Calkins AS, Szalat R, Dreze M, Khan I, Frazier Z, Reznichenkov E, Schnorenberg MR, Tsai YF, Nguyen H, Kochupurakkal B, D'Andrea AD, Shapiro GI, Lazaro JB, Mouw KW. Functional profiling of nucleotide Excision repair in breast cancer. DNA Repair (Amst). 2019 10; 82:102697. PMID: 31499327.
    Citations: 1     Fields:    Translation:HumansCells
  18. Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res. 2019 10 15; 25(20):6127-6140. PMID: 31409614.
    Citations: 9     Fields:    Translation:HumansCells
  19. Hill SJ, D'Andrea AD. Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids. Cancer Discov. 2019 Jul; 9(7):828-830. PMID: 31262743.
    Citations: 1     Fields:    Translation:Humans
  20. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Jun 13.